Moderna Inc
NASDAQ:MRNA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
36.85
166.61
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Moderna Inc
Wall Street
Price Targets
MRNA Price Targets Summary
Moderna Inc
According to Wall Street analysts, the average 1-year price target for
MRNA
is 77.99 USD
with a low forecast of 31.31 USD and a high forecast of 222.6 USD.
MRNA Last Price Targets
Moderna Inc
The latest public price target was made on Nov 18, 2024 by
Yifeng Liu
from
HSBC
,
who expects
MRNA
stock to
rise by 47%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Yifeng Liu
HSBC
|
58
USD
Upside 47% |
1 month ago
Nov 18, 2024
|
HSBC Upgrades Moderna (MRNA) to Buy
StreetInsider
|
Edward Tenthoff
Piper Sandler
|
69
USD
Upside 75% |
1 month ago
Nov 18, 2024
|
Moderna (MRNA) PT Lowered to $69 at Piper Sandler
StreetInsider
|
Courtney Breen
Bernstein
|
55
USD
Upside 40% |
2 months ago
Oct 17, 2024
|
Moderna initiated with a Market Perform at Bernstein
TheFly
|
Michael Yee
Jefferies
|
55
USD
Upside 40% |
2 months ago
Oct 14, 2024
|
Moderna price target lowered to $55 from $65 at Jefferies
TheFly
|
Leah Rush Cann
Loop Capital Markets
|
238
USD
Upside 504% |
3 months ago
Sep 13, 2024
|
Moderna (MRNA) PT Lowered to $238 at Brookline Capital Markets
StreetInsider
|
Luca Issi
RBC Capital
|
75
USD
Upside 90% |
3 months ago
Sep 13, 2024
|
Moderna (MRNA) PT Lowered to $75 at RBC Capital
StreetInsider
|
|
Edward Tenthoff
Piper Sandler
|
115
USD
Upside 192% |
3 months ago
Sep 13, 2024
|
Moderna (MRNA) PT Lowered to $115 at Piper Sandler
StreetInsider
|
Matthew Harrison
Morgan Stanley
|
94
USD
Upside 139% |
3 months ago
Sep 12, 2024
|
Morgan Stanley on Moderna (MRNA): 'we expect MRNA shares to trade off this morning'
StreetInsider
|
Cory Kasimov
Evercore ISI
|
105
USD
Upside 167% |
3 months ago
Sep 12, 2024
|
Evercore ISI Reiterates In Line Rating on Moderna (MRNA)
StreetInsider
|
|
Michael Yee
Jefferies
|
120
USD
Upside 205% |
3 months ago
Sep 12, 2024
|
Jefferies Reiterates Buy Rating on Moderna (MRNA)
StreetInsider
|
Peter Arment
Robert W. Baird
|
220
USD
Upside 459% |
3 months ago
Aug 28, 2024
|
This Moderna Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Benzinga
|
|
Yifeng Liu
HSBC
|
82
USD
Upside 108% |
3 months ago
Aug 28, 2024
|
Moderna upgraded to Hold from Reduce at HSBC
TheFly
|
Emmanuel Papadakis
Deutsche Bank
|
80
USD
Upside 103% |
4 months ago
Aug 6, 2024
|
Moderna upgraded to Hold at Deutsche with risk-reward looking more balanced
TheFly
|
|
Luca Issi
RBC Capital
|
90
USD
Upside 128% |
4 months ago
Aug 5, 2024
|
Moderna downgraded to Sector Perform from Outperform at RBC Capital
TheFly
|
|
Edward Tenthoff
Piper Sandler
|
157
USD
Upside 299% |
4 months ago
Aug 2, 2024
|
Moderna price target lowered to $157 from $214 at Piper Sandler
TheFly
|
Hartaj Singh
Oppenheimer
|
179
USD
Upside 354% |
6 months ago
Jun 12, 2024
|
Moderna price target raised to $179 from $163 at Oppenheimer
TheFly
|
|
Leah Rush Cann
Loop Capital Markets
|
310
USD
Upside 687% |
6 months ago
Jun 10, 2024
|
Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA)
StreetInsider
|
|
Michael Yee
Jefferies
|
180
USD
Upside 357% |
6 months ago
Jun 7, 2024
|
Moderna price target raised to $180 from $155 at Jefferies
TheFly
|
|
Luca Issi
RBC Capital
|
160
USD
Upside 306% |
6 months ago
May 31, 2024
|
Moderna price target raised to $160 from $135 at RBC Capital
TheFly
|
|
Cory Kasimov
Evercore ISI
|
120
USD
Upside 205% |
7 months ago
May 13, 2024
|
Evercore ISI Starts Moderna (MRNA) at In Line
StreetInsider
|
|
Emmanuel Papadakis
Deutsche Bank
|
85
USD
Upside 116% |
7 months ago
May 9, 2024
|
Moderna price target raised to $85 from $70 at Deutsche Bank
TheFly
|
Eliana Merle
UBS
|
151
USD
Upside 283% |
7 months ago
May 7, 2024
|
Moderna price target raised to $151 from $143 at UBS
TheFly
|
|
Michael Yee
Jefferies
|
155
USD
Upside 294% |
7 months ago
May 3, 2024
|
Moderna price target raised to $155 from $125 at Jefferies
TheFly
|
|
Luca Issi
RBC Capital
|
135
USD
Upside 243% |
7 months ago
May 3, 2024
|
Moderna (MRNA) PT Raised to $135 at RBC Capital
StreetInsider
|
|
Hartaj Singh
Oppenheimer
|
163
USD
Upside 314% |
7 months ago
May 3, 2024
|
Moderna (MRNA) PT Raised to $163 at Oppenheimer
StreetInsider
|
Bill Maughan
Canaccord Genuity
|
106
USD
Upside 169% |
7 months ago
May 3, 2024
|
Moderna price target raised to $106 from $91 at Canaccord
TheFly
|
|
Matthew Harrison
Morgan Stanley
|
95
USD
Upside 141% |
7 months ago
May 2, 2024
|
Moderna (MRNA) PT Raised to $95 at Morgan Stanley
StreetInsider
|
|
Matthew Harrison
Morgan Stanley
|
89
USD
Upside 126% |
7 months ago
Apr 24, 2024
|
Morgan Stanley Comments on Moderna (MRNA) Collaboration with OpenAI
StreetInsider
|
|
Michael Yee
Jefferies
|
125
USD
Upside 217% |
8 months ago
Mar 28, 2024
|
Moderna (MRNA) PT Raised to $125 at Jefferies ahead of RSV launch and CMV data
StreetInsider
|
|
Eliana Merle
UBS
|
143
USD
Upside 263% |
8 months ago
Mar 27, 2024
|
UBS Reiterates Buy Rating on Moderna (MRNA)
StreetInsider
|
|
Bill Maughan
Canaccord Genuity
|
82
USD
Upside 108% |
10 months ago
Feb 22, 2024
|
Moderna Likely To Report Q4 Loss; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Benzinga
|
|
Matthew Harrison
Morgan Stanley
|
123
USD
Upside 212% |
10 months ago
Feb 22, 2024
|
Moderna Likely To Report Q4 Loss; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Benzinga
|
|
Hartaj Singh
Oppenheimer
|
142
USD
Upside 260% |
11 months ago
Jan 2, 2024
|
Moderna Analyst Projects Transformation Into 'Five-Product Commercial Company' By 2026
Benzinga
|
|
Eliana Merle
UBS
|
191
USD
Upside 385% |
1 year ago
Jun 26, 2023
|
Moderna Pipeline For Any Vaccine Beyond Covid Is 'Underappreciated,' Analyst Says
Benzinga
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is MRNA's stock price target?
Price Target
77.99
USD
According to Wall Street analysts, the average 1-year price target for
MRNA
is 77.99 USD
with a low forecast of 31.31 USD and a high forecast of 222.6 USD.
What is Moderna Inc's Revenue forecast?
Projected CAGR
-8%
For the last 6 years the
compound annual growth rate for
Moderna Inc's revenue is
79%.
The projected
CAGR
for the next 4 years is
-8%.
You don't have any saved screeners yet
